Supplemental ubiquinol in patients with advanced congestive heart failure

BioFactors

Volumn 32, Issue 1-4, 2008, Pages 119-128

  Langsjoen, Peter H ^a,c   Langsjoen, Alena M ^b  

^a EAST TEXAS MEDICAL CENTER   (United States)

^b Coenzyme Q10 Laboratory Inc ^*  (United States)

^c NONE   (United States)

Author keywords

Cholesterol; Class IV congestive heart failure; Coenzyme Q10; CoQ10; End stage CHF; Ubiquinol; Ubiquinone; Vitamin E

Indexed keywords

UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUINONE;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HUMAN; INTESTINE ABSORPTION; MALE; PRIORITY JOURNAL;

EID: 58149394349     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520320114     Document Type: Conference Paper

References (29)

1. 10 and exercise training in chronic heart failure, Eur Heart J 27(22) (Nov 2006), 2675-2681. Epub 2006 Aug 1.
2. 10 improves contractility of dysfunctional myocardium in chronic heart failure, Biofactors 25(1-4) (2005), 137-145.
3. K. Hashiba, K. Kuramoto, Z. Ishimi, K. Kato, K. Seki, K. Taniguchi, T. Taya, F. Terawasa, S. Torii, J. Fijii, N. Yamazaki and H. Watanabe, Heart 4 (1972), 1579-1589 [in Japanese].
4. R.E. Hershberger, D. Nauman, T.L. Walker, D. Dutton and D. Burgess, Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure, J Card Fail 9(3) (Jun 2003), 180-187.
5. K. Hosoe, M. Kitano, H. Kishida, H. Kubo, K. Fujii and M. Kitahara, Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers, Regul Toxicol Pharmacol 47(1) (Feb 2007), 19-28. Epub 2006 Aug 21.
6. T. Iwabuchi, N. Kato, N. Goto, Y. Higuchi, S. Takaola, Y. Iwaki, E. Shidara, M. Yoshimura and J. Atarashi, Jpn J Clin Exp Med 49 (1972), 2604-2608 [in Japanese].
7. 10 in heart failure, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 315-323.
8. 10 treated congestive heart failure patients compared to conventionally treated patients, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, K. Folkers, G.P. Littarru and T. Yamagami, eds, Elsevier, Amsterdam, 1991, pp. 291-298.
9. M. Khatta, B.S. Alexander, C.M. Krichten, M.L. Fisher, R. Freudenberger, S.W. Robinson and S.S. Gottlieb, The effect of coenzyme Q10 in patients with congestive heart failure, Annals of Internal Medicine 132 (2000), 641-648.
10. P.H. Langsjoen, S. Vadhanavikit and K. Folkers, Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10, Proceedings of the National Acadademy of Sciences, USA 82 (1985), 4240-4244.
11. 10 therapy for idiopathic dilated cardiomyopathy, Am J Cardiol 65(7) (Feb 1990), 521-523.
12. A. Ma, W. Zhang and Z. Liu, Effect of protection and repair of injury of mitochondrial membranephospholipid on prognosis in patients with dilated cardiomyopathy, Blood Press 3 (1996), 53-58.
13. P. Meurin, [Shoshin beriberi, A rapidly curable hemodynamic disaster] [Article in French], Presse Med 25(24) (Jul 1996), 6-13, 1115-1118.
14. 10 therapy in patients with congestive heart failure: A long-term multicenter randomized study, Clinical Investigator 71 (1993), s134-s136.
15. 10 treatment, Molecular Aspects of Medicine 15 (1994), s155-163.
16. 10 treatment in heart failure, BioFactors 9(2-4) (1999), 285-289.
17. 10 on load-induced cardiac dysfunction: Double blind study and investigation of doseresponse relationship, in: Highlights in Ubiquinone Research, G. Lenaz, O. Barnabei, A. Rabbi and M. Battino, eds, Taylor and Francis, London, 1990, pp. 232-237.
18. 10) in the long-term treatment of idiopathic dilated cardiomyopathy, European Heart J 13(11) (Nov 1992), 1528-1533.
19. L. Poggesi, G. Galanti, M. Comeglio, L. Toncelli and M. Vinci, Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. A medium-term randomized double-blind study versus placebo, Current Therapeutic Research 49(5) (1991), 878-886.
20. F. Rengo, P. Abete, P. Landino, D. Leosco, F. Covelluzzi, D. Vitale, V. Fedi and N. Ferrara, Role of metabolic therapy in cardiovascular disease, The Clinical Investigator 71(1993), s124-s128.
21. 10 in ischaemic cardiopathy, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6 K. Folkers, T. Yamagami and G.P. Littarru, eds, Elsevier, Amsterdam, 1991, pp. 321-326.
22. 10 on patients with cardiac disease, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 325-333.
23. 10 in patients with moderate heart failure and chonic stable effors angina, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6, K. Folkers, G.P. Littarru and T. Yamagami, eds, Elsevier, Amsterdam, 1991, pp. 327-338.
24. 10 as an adjunctive in treatment of congestive heart failure, J Cardiac Failure 1 (1995), 101-107.
25. 10 on physical performance and recovery in myocardial failure, in: Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1986, pp. 371-377.
26. P.S. Watson, G.M. Scalia, A. Galbraith, D.J. Burstow, N. Bett and C.N. Aroney, Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure, J Am Coll Cardiol 33 (1999), 1549-1552.
27. Y. Yamamura, Clinical status of coenzyme Q and prospects, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, Elsevier, Amsterdam, 1977, pp. 281-298.
28. Y. Yamamura, Asurvey of the therapeutic uses of coenzyme Q, in: Coenzyme Q. Biochemistry, Bioenergetics and Clinical Applications of Ubiquinone, G. Lenaz, ed., John Wiley & Sons, 1985, pp. 479-505.
29. S. Yamashita and Y. Yamamoto, Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress, Analytical Biochemistry 25 (1997), 66-73.